Cargando…

Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms

BACKGROUND: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound “Tradamixina plus Serenoa Repens” in order to improve lower urinary tract symptoms. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Iacono, Fabrizio, Prezioso, Domenico, Illiano, Ester, Ruffo, Antonio, Romeo, Giuseppe, Amato, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499205/
https://www.ncbi.nlm.nih.gov/pubmed/23173650
http://dx.doi.org/10.1186/1471-2482-12-S1-S22
_version_ 1782249917710860288
author Iacono, Fabrizio
Prezioso, Domenico
Illiano, Ester
Ruffo, Antonio
Romeo, Giuseppe
Amato, Bruno
author_facet Iacono, Fabrizio
Prezioso, Domenico
Illiano, Ester
Ruffo, Antonio
Romeo, Giuseppe
Amato, Bruno
author_sort Iacono, Fabrizio
collection PubMed
description BACKGROUND: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound “Tradamixina plus Serenoa Repens” in order to improve lower urinary tract symptoms. METHODS: 100 patients (≥45years) who had had LUTS/BPH for >6 mo at screening and with IPSS -The international Prostate symptom scores- ≥13 and maximum urinary flow rate (Qmax) ≥4 to ≤15 ml/s. were recruited. The compound “Tradamixina plus Serenoa Repens” (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mg of D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) was administered daily for 2 months. At visit and after 60 days of treatment patients were evaluated by means of detailed medical urological history, clinical examination, laboratory investigations (total PSA), and instrumental examination like urolfowmetry. Efficacy measures included IPSS-International Prostate Sympto, BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed at baseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wk for IPSS, and 4 wk for BII. Statistical significance was interpreted only if the results of the preceding analysis were significant at the 0.05 level. RESULTS: After 2 months of treatment the change from baseline to week 12 relative to “Tradamixina plus Seronea Repens” in total IPSS and Qol was statistically significant. Differences from baseline in BII were statistically significant for “Tradamixina plus Seronea Repens” above all differences in BII were also significant at 4 wk (LSmean ± SE: -0.8 ± 0.2). In the distribution of subjects over the PGI-I and CGI-I response categories were significant for”Tradamixina plus Seronea Repens” (PGI-I: p = 0.001; CGI-I). We also observed a decrease of total PSA. CONCLUSION: The daily treatment with a new compound “Tradamixina plus Serenoa Repens” for 2 months improved the male sexual function , it improved the bother symptoms which affect the patient’s quality of life , improved uroflowmetric parameters, and we also observed a decrease of serum PSA level.
format Online
Article
Text
id pubmed-3499205
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34992052012-11-20 Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms Iacono, Fabrizio Prezioso, Domenico Illiano, Ester Ruffo, Antonio Romeo, Giuseppe Amato, Bruno BMC Surg Research Article BACKGROUND: Lower urinary tract symptoms (LUTS) are associated with great emotional costs to individuals and substantial economic costs to society. This study seeks to evaluate the effect of a new natural compound “Tradamixina plus Serenoa Repens” in order to improve lower urinary tract symptoms. METHODS: 100 patients (≥45years) who had had LUTS/BPH for >6 mo at screening and with IPSS -The international Prostate symptom scores- ≥13 and maximum urinary flow rate (Qmax) ≥4 to ≤15 ml/s. were recruited. The compound “Tradamixina plus Serenoa Repens” (80 mg of Alga Ecklonia Bicyclis, 100 mg of Tribulus Terrestris and 100 mg of D-Glucosamine and N-Acetyl-D-Glucosamine plus 320 mg of Serenoa Repens) was administered daily for 2 months. At visit and after 60 days of treatment patients were evaluated by means of detailed medical urological history, clinical examination, laboratory investigations (total PSA), and instrumental examination like urolfowmetry. Efficacy measures included IPSS-International Prostate Sympto, BPH Impact Index (BII), Quality-of-Life (QoL) Index. Measures were assessed at baseline and end point (12 wk or end of therapy) and also at screening, 1 and 4 wk for IPSS, and 4 wk for BII. Statistical significance was interpreted only if the results of the preceding analysis were significant at the 0.05 level. RESULTS: After 2 months of treatment the change from baseline to week 12 relative to “Tradamixina plus Seronea Repens” in total IPSS and Qol was statistically significant. Differences from baseline in BII were statistically significant for “Tradamixina plus Seronea Repens” above all differences in BII were also significant at 4 wk (LSmean ± SE: -0.8 ± 0.2). In the distribution of subjects over the PGI-I and CGI-I response categories were significant for”Tradamixina plus Seronea Repens” (PGI-I: p = 0.001; CGI-I). We also observed a decrease of total PSA. CONCLUSION: The daily treatment with a new compound “Tradamixina plus Serenoa Repens” for 2 months improved the male sexual function , it improved the bother symptoms which affect the patient’s quality of life , improved uroflowmetric parameters, and we also observed a decrease of serum PSA level. BioMed Central 2012-11-15 /pmc/articles/PMC3499205/ /pubmed/23173650 http://dx.doi.org/10.1186/1471-2482-12-S1-S22 Text en Copyright ©2012 Iacono et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Iacono, Fabrizio
Prezioso, Domenico
Illiano, Ester
Ruffo, Antonio
Romeo, Giuseppe
Amato, Bruno
Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title_full Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title_fullStr Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title_full_unstemmed Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title_short Observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
title_sort observational study: daily treatment with a new compound “tradamixina” plus serenoa repens for two months improved the lower urinary tract symptoms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499205/
https://www.ncbi.nlm.nih.gov/pubmed/23173650
http://dx.doi.org/10.1186/1471-2482-12-S1-S22
work_keys_str_mv AT iaconofabrizio observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms
AT preziosodomenico observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms
AT illianoester observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms
AT ruffoantonio observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms
AT romeogiuseppe observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms
AT amatobruno observationalstudydailytreatmentwithanewcompoundtradamixinaplusserenoarepensfortwomonthsimprovedthelowerurinarytractsymptoms